Upstate Active Clinical Trials

Study Title:

Phase II Randomized, Prospective Trial of Lutetium Lu 177 DOTATATE PRRT versus Capecitabine and Temozolomide in Well-differentiated Pancreatic Neuroendocrine Tumors

What is the purpose of the study? (in Layman's terms, please describe the study)

The purpose of this study is to compare the combination of two oral chemotherapy drugs, temozolomide and capecitabine, to using lutetium Lu 177 dotatate, a radioactive drug given through your vein, and to find out if this different approach is better, the same, or worse than the usual approach.

Upstate Institutional Review Board (IRB) Number:

1954162

Study/Protocol ID:

A022001

Study Phase:

II

Patient Age Group:

Adults

Principal Investigator:

Rahul Seth, DO

What is involved if I participate?

• How long is the study?
  8 years
• Is transportation provided or reimbursed?
  No
• Is parking provided or reimbursed?
  No
• What tests and procedures are involved?
  laboratory blood tests, scans

Where will the study take place?

Upstate Cancer Center

Other Information:

N/a

ClinicalTrials.Gov ID:

NCT05247905

For more information about this trial go to ClinicalTrials.Gov

Who can I contact for more information?

Name: Amelia Bell
Phone: 315-464-5777
Email: [email protected]

Return to Previous Page || Search Again